TD Cowen Reiterates Buy Rating on Krystal Biotech, Inc. (KRYS)

Market Context

Krystal Biotech, Inc. operates in the Healthcare sector. The stock currently trades at $305.03 with a market capitalization of $7.2B. The stock has gained 48.0% over the past 52 weeks.

Analyst coverage from TD Cowen provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Krystal Biotech, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Krystal Biotech, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 03, 2026	RBC Capital	Outperform	N/A
Nov 03, 2026	TD Cowen	Buy	N/A
Nov 03, 2026	Citigroup	Buy	N/A
Oct 15, 2026	HC Wainwright & Co.	Buy	N/A
Sep 24, 2026	Goldman Sachs	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View KRYS Stock Page